- Home
- AEF vs EDIT Comparison
AEF vs EDIT Comparison
Compare AEF & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEF
- EDIT
- Stock Information
- Founded
- AEF 1989
- EDIT 2013
- Country
- AEF United States
- EDIT United States
- Employees
- AEF N/A
- EDIT N/A
- Industry
- AEF Finance/Investors Services
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AEF Finance
- EDIT Health Care
- Exchange
- AEF Nasdaq
- EDIT Nasdaq
- Market Cap
- AEF 264.3M
- EDIT 269.8M
- IPO Year
- AEF N/A
- EDIT 2016
- Fundamental
- Price
- AEF $6.69
- EDIT $4.22
- Analyst Decision
- AEF
- EDIT Buy
- Analyst Count
- AEF 0
- EDIT 11
- Target Price
- AEF N/A
- EDIT $4.56
- AVG Volume (30 Days)
- AEF 92.5K
- EDIT 3.4M
- Earning Date
- AEF 01-01-0001
- EDIT 11-03-2025
- Dividend Yield
- AEF 7.13%
- EDIT N/A
- EPS Growth
- AEF N/A
- EDIT N/A
- EPS
- AEF 0.57
- EDIT N/A
- Revenue
- AEF N/A
- EDIT $38,901,000.00
- Revenue This Year
- AEF N/A
- EDIT N/A
- Revenue Next Year
- AEF N/A
- EDIT N/A
- P/E Ratio
- AEF $8.86
- EDIT N/A
- Revenue Growth
- AEF N/A
- EDIT N/A
- 52 Week Low
- AEF $4.40
- EDIT $0.91
- 52 Week High
- AEF $5.53
- EDIT $4.54
- Technical
- Relative Strength Index (RSI)
- AEF 63.82
- EDIT 63.89
- Support Level
- AEF $6.56
- EDIT $3.64
- Resistance Level
- AEF $6.67
- EDIT $4.33
- Average True Range (ATR)
- AEF 0.11
- EDIT 0.38
- MACD
- AEF 0.01
- EDIT -0.00
- Stochastic Oscillator
- AEF 97.73
- EDIT 73.12
About AEF abrdn Emerging Markets Equity Income Fund Inc.
ABERDEEN EMERGING MARKETS EQUITY INCOME FUND, INC. is a closed-end investment company. The Fund's investment objective is to seek to provide both current income and long-term capital appreciation. The Fund invests in a range of sectors, including financials, consumer staples, utilities, consumer discretionary, materials, energy, information technology, private equity, communication services, healthcare, real estate, and industrials.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.